{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:29:03Z","timestamp":1790393343204,"version":"4.1.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100010029","name":"Taishan Scholar Foundation of Shandong Province","doi-asserted-by":"publisher","award":["tsqn202312391"],"award-info":[{"award-number":["tsqn202312391"]}],"id":[{"id":"10.13039\/501100010029","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010029","name":"Taishan Scholar Foundation of Shandong Province","doi-asserted-by":"publisher","award":["tsqn202408400"],"award-info":[{"award-number":["tsqn202408400"]}],"id":[{"id":"10.13039\/501100010029","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82501704"],"award-info":[{"award-number":["82501704"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-07939-z","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T16:24:33Z","timestamp":1772209473000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Baseline plasma p-tau217\/A\u03b242 as a sensitive marker for the severity of Alzheimer\u2019s disease continuum"],"prefix":"10.1186","volume":"24","author":[{"given":"Wen-Zheng","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze-Hu","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Qian","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Hui","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie-Qiong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Hui","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Nan","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"For the Alzheimer\u2019s Disease Neuroimaging Initiative","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"7939_CR1","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","volume":"27","author":"O Hansson","year":"2021","unstructured":"Hansson O. Biomarkers for neurodegenerative diseases. Nat Med. 2021;27:954\u201363.","journal-title":"Nat Med"},{"key":"7939_CR2","doi-asserted-by":"crossref","unstructured":"Alzheimer\u2019s Association. 2023 Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2023;19:1598\u20131695.","DOI":"10.1002\/alz.13016"},{"key":"7939_CR3","doi-asserted-by":"publisher","first-page":"398","DOI":"10.14283\/jpad.2021.41","volume":"8","author":"J Cummings","year":"2021","unstructured":"Cummings J, Aisen P, Apostolova LG, Atri A, Salloway S, Weiner M. Aducanumab: Appropriate Use Recommendations. J Prev Alzheimers Dis. 2021;8:398\u2013410.","journal-title":"J Prev Alzheimers Dis"},{"key":"7939_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, et al. Lecanemab in Early Alzheimer\u2019s Disease. N Engl J Med. 2023;388:9\u201321.","journal-title":"N Engl J Med"},{"key":"7939_CR5","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul Nery ES, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023;330:512\u201327.","journal-title":"JAMA"},{"key":"7939_CR6","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13195-024-01469-w","volume":"16","author":"Y Niimi","year":"2024","unstructured":"Niimi Y, Janelidze S, Sato K, Tomita N, Tsukamoto T, Kato T, Yoshiyama K, Kowa H, Iwata A, Ihara R, et al. Combining plasma A\u03b2 and p-tau217 improves detection of brain amyloid in non-demented elderly. Alzheimers Res Ther. 2024;16:115.","journal-title":"Alzheimers Res Ther"},{"key":"7939_CR7","doi-asserted-by":"publisher","first-page":"6747","DOI":"10.1038\/s41467-023-42596-6","volume":"14","author":"H Cai","year":"2023","unstructured":"Cai H, Pang Y, Fu X, Ren Z, Jia L. Plasma biomarkers predict Alzheimer\u2019s disease before clinical onset in Chinese cohorts. Nat Commun. 2023;14:6747.","journal-title":"Nat Commun"},{"key":"7939_CR8","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1002\/alz.12332","volume":"17","author":"JR Chong","year":"2021","unstructured":"Chong JR, Ashton NJ, Karikari TK, Tanaka T, Saridin FN, Reilhac A, Robins EG, Nai YH, Vrooman H, Hilal S, et al. Plasma p-tau181 to A\u03b242 ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer\u2019s disease patients with concomitant cerebrovascular disease. Alzheimers Dement. 2021;17:1649\u201362.","journal-title":"Alzheimers Dement"},{"key":"7939_CR9","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1001\/jama.2019.2000","volume":"321","author":"GD Rabinovici","year":"2019","unstructured":"Rabinovici GD, Gatsonis C, Apgar C, Chaudhary K, Gareen I, Hanna L, Hendrix J, Hillner BE, Olson C, Lesman-Segev OH, et al. Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia. JAMA. 2019;321:1286\u201394.","journal-title":"JAMA"},{"key":"7939_CR10","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1001\/jama.2009.1064","volume":"302","author":"N Mattsson","year":"2009","unstructured":"Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. 2009;302:385\u201393.","journal-title":"JAMA"},{"key":"7939_CR11","first-page":"1797","volume":"28","author":"M Mil\u00e0-Alom\u00e0","year":"2022","unstructured":"Mil\u00e0-Alom\u00e0 M, Ashton NJ, Shekari M, Salvad\u00f3 G, Ortiz-Romero P, Montoliu-Gaya L, Benedet AL, Karikari TK, Lantero-Rodriguez J, Vanmechelen E, et al. Plasma p-tau231 and p-tau217 as state markers of amyloid-\u03b2 pathology in preclinical Alzheimer\u2019s disease. Nat Med. 2022;28:1797\u2013801.","journal-title":"Nat Med"},{"key":"7939_CR12","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, Su Y, Chen Y, Serrano GE, Leuzy A, et al. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA. 2020;324:772\u201381.","journal-title":"JAMA"},{"key":"7939_CR13","doi-asserted-by":"publisher","first-page":"e14430","DOI":"10.1002\/alz.14430","volume":"21","author":"M Olvera-Rojas","year":"2025","unstructured":"Olvera-Rojas M, Sewell KR, Karikari TK, Huang H, Oberlin LE, Zeng X, Morris JK, Collins AM, Drake JA, Sutton BP, et al. Influence of medical conditions on the diagnostic accuracy of plasma p-tau217 and p-tau217\/A\u03b242. Alzheimers Dement. 2025;21:e14430.","journal-title":"Alzheimers Dement"},{"key":"7939_CR14","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1136\/jnnp-2024-334122","volume":"96","author":"J Hazan","year":"2025","unstructured":"Hazan J, Abel E, Rosa Grilo M, Alawode D, Laranjinha I, Heslegrave AJ, Liu KY, Schott JM, Howard R, Zetterberg H, Fox NC. How well do plasma Alzheimer\u2019s disease biomarkers reflect the CSF amyloid status? J Neurol Neurosurg Psychiatry. 2025;96:566\u201372.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"7939_CR15","doi-asserted-by":"publisher","first-page":"e70038","DOI":"10.1002\/alz.70038","volume":"21","author":"J Wang","year":"2025","unstructured":"Wang J, Huang S, Lan G, Lai YJ, Wang QH, Chen Y, Xiao ZS, Chen X, Bu XL, Liu YH, et al. Diagnostic accuracy of plasma p-tau217\/A\u03b242 for Alzheimer\u2019s disease in clinical and community cohorts. Alzheimers Dement. 2025;21:e70038.","journal-title":"Alzheimers Dement"},{"key":"7939_CR16","doi-asserted-by":"publisher","first-page":"4463","DOI":"10.1002\/alz.13393","volume":"19","author":"PCL Ferreira","year":"2023","unstructured":"Ferreira PCL, Therriault J, Tissot C, Ferrari-Souza JP, Benedet AL, Povala G, Bellaver B, Leffa DT, Brum WS, Lussier FZ, et al. Plasma p-tau231 and p-tau217 inform on tau tangles aggregation in cognitively impaired individuals. Alzheimers Dement. 2023;19:4463\u201374.","journal-title":"Alzheimers Dement"},{"key":"7939_CR17","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1001\/jamaneurol.2022.5272","volume":"80","author":"N Mattsson-Carlgren","year":"2023","unstructured":"Mattsson-Carlgren N, Salvad\u00f3 G, Ashton NJ, Tideman P, Stomrud E, Zetterberg H, Ossenkoppele R, Betthauser TJ, Cody KA, Jonaitis EM, et al. Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers. JAMA Neurol. 2023;80:360\u20139.","journal-title":"JAMA Neurol"},{"key":"7939_CR18","doi-asserted-by":"crossref","unstructured":"Dakterzada F, L\u00f3pez-Ortega R, Vilella-Figuerola A, Montero-Castilla N, Riba-Llena I, Ruiz-Juli\u00e1n M, Arias A, Sarto J, Tahan N, Pi\u00f1ol-Ripoll G. Performance of plasma phosphorylated tau-217 in patients on the continuum of Alzheimer\u2019s disease. Int J Mol Sci. 2025;26.","DOI":"10.3390\/ijms26146771"},{"key":"7939_CR19","doi-asserted-by":"publisher","first-page":"e70355","DOI":"10.1002\/alz.70355","volume":"21","author":"CR Vanderlip","year":"2025","unstructured":"Vanderlip CR, Stark CEL. Integrating plasma p-tau217 and digital cognitive assessments for early detection in Alzheimer\u2019s disease. Alzheimers Dement. 2025;21:e70355.","journal-title":"Alzheimers Dement"},{"key":"7939_CR20","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1038\/s41591-022-02074-w","volume":"28","author":"NJ Ashton","year":"2022","unstructured":"Ashton NJ, Janelidze S, Mattsson-Carlgren N, Binette AP, Strandberg O, Brum WS, Karikari TK, Gonz\u00e1lez-Ortiz F, Di Molfetta G, Meda FJ, et al. Differential roles of A\u03b242\/40, p-tau231 and p-tau217 for Alzheimer\u2019s trial selection and disease monitoring. Nat Med. 2022;28:2555\u201362.","journal-title":"Nat Med"},{"key":"7939_CR21","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3389\/fmed.2017.00203","volume":"4","author":"GAM Dolci","year":"2017","unstructured":"Dolci GAM, Damanti S, Scortichini V, Galli A, Rossi PD, Abbate C, Arosio B, Mari D, Arighi A, Fumagalli GG, et al. Alzheimer\u2019s Disease Diagnosis: Discrepancy between Clinical, Neuroimaging, and Cerebrospinal Fluid Biomarkers Criteria in an Italian Cohort of Geriatric Outpatients: A Retrospective Cross-sectional Study. Front Med (Lausanne). 2017;4:203.","journal-title":"Front Med (Lausanne)"},{"key":"7939_CR22","first-page":"434","volume":"144","author":"A Keshavan","year":"2021","unstructured":"Keshavan A, Pannee J, Karikari TK, Rodriguez JL, Ashton NJ, Nicholas JM, Cash DM, Coath W, Lane CA, Parker TD, et al. Population-based blood screening for preclinical Alzheimer\u2019s disease in a British birth cohort at age 70. Brain. 2021;144:434\u201349.","journal-title":"Brain"},{"key":"7939_CR23","doi-asserted-by":"publisher","first-page":"e14536","DOI":"10.1002\/alz.14536","volume":"21","author":"X Zhong","year":"2025","unstructured":"Zhong X, Wang Q, Yang M, Lin G, Yao K, Wu Z, Xu D, Zhou H, Chen B, Shi H, et al. Plasma p-tau217 and p-tau217\/A\u03b21\u201342 are effective biomarkers for identifying CSF- and PET imaging-diagnosed Alzheimer\u2019s disease: Insights for research and clinical practice. Alzheimers Dement. 2025;21:e14536.","journal-title":"Alzheimers Dement"},{"key":"7939_CR24","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1212\/WNL.0b013e3181cb3e25","volume":"74","author":"RC Petersen","year":"2010","unstructured":"Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, Jack CR Jr., Jagust WJ, Shaw LM, Toga AW, et al. Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. 2010;74:201\u20139.","journal-title":"Neurology"},{"key":"7939_CR25","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13195-024-01513-9","volume":"16","author":"J Arranz","year":"2024","unstructured":"Arranz J, Zhu N, Rubio-Guerra S, Rodr\u00edguez-Baz \u00cd, Ferrer R, Carmona-Iragui M, Barroeta I, Ill\u00e1n-Gala I, Santos-Santos M, Fortea J, et al. Diagnostic performance of plasma pTau(217), pTau(181), A\u03b2(1\u201342) and A\u03b2(1\u201340) in the LUMIPULSE automated platform for the detection of Alzheimer disease. Alzheimers Res Ther. 2024;16:139.","journal-title":"Alzheimers Res Ther"},{"key":"7939_CR26","doi-asserted-by":"publisher","first-page":"e14264","DOI":"10.1002\/alz.14264","volume":"21","author":"LM Shaw","year":"2025","unstructured":"Shaw LM, Korecka M, Lee EB, Cousins KAQ, Vanderstichele H, Schindler SE, Tosun D, DeMarco ML, Brylska M, Wan Y, et al. ADNI Biomarker Core: A review of progress since 2004 and future challenges. Alzheimers Dement. 2025;21:e14264.","journal-title":"Alzheimers Dement"},{"key":"7939_CR27","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/ana.21610","volume":"65","author":"LM Shaw","year":"2009","unstructured":"Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, et al. Cerebrospinal fluid biomarker signature in Alzheimer\u2019s disease neuroimaging initiative subjects. Ann Neurol. 2009;65:403\u201313.","journal-title":"Ann Neurol"},{"key":"7939_CR28","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.jalz.2018.01.010","volume":"14","author":"O Hansson","year":"2018","unstructured":"Hansson O, Seibyl J, Stomrud E, Zetterberg H, Trojanowski JQ, Bittner T, Lifke V, Corradini V, Eichenlaub U, Batrla R, et al. CSF biomarkers of Alzheimer\u2019s disease concord with amyloid-\u03b2 PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement. 2018;14:1470\u201381.","journal-title":"Alzheimers Dement"},{"key":"7939_CR29","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/jamaneurol.2023.2338","volume":"80","author":"P Erickson","year":"2023","unstructured":"Erickson P, Simr\u00e9n J, Brum WS, Ennis GE, Kollmorgen G, Suridjan I, Langhough R, Jonaitis EM, Van Hulle CA, Betthauser TJ, et al. Prevalence and Clinical Implications of a \u03b2-Amyloid-Negative, Tau-Positive Cerebrospinal Fluid Biomarker Profile in Alzheimer Disease. JAMA Neurol. 2023;80:969\u201379.","journal-title":"JAMA Neurol"},{"key":"7939_CR30","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1159\/000230709","volume":"28","author":"JF Benge","year":"2009","unstructured":"Benge JF, Balsis S, Geraci L, Massman PJ, Doody RS. How well do the ADAS-cog and its subscales measure cognitive dysfunction in Alzheimer\u2019s disease? Dement Geriatr Cogn Disord. 2009;28:63\u20139.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"7939_CR31","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189\u201398.","journal-title":"J Psychiatr Res"},{"key":"7939_CR32","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s11682-012-9176-1","volume":"6","author":"LE Gibbons","year":"2012","unstructured":"Gibbons LE, Carle AC, Mackin RS, Harvey D, Mukherjee S, Insel P, Curtis SM, Mungas D, Crane PK. A composite score for executive functioning, validated in Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. Brain Imaging Behav. 2012;6:517\u201327.","journal-title":"Brain Imaging Behav"},{"key":"7939_CR33","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1007\/s11682-012-9186-z","volume":"6","author":"PK Crane","year":"2012","unstructured":"Crane PK, Carle A, Gibbons LE, Insel P, Mackin RS, Gross A, Jones RN, Mukherjee S, Curtis SM, Harvey D, et al. Development and assessment of a composite score for memory in the Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI). Brain Imaging Behav. 2012;6:502\u201316.","journal-title":"Brain Imaging Behav"},{"key":"7939_CR34","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/jmri.21049","volume":"27","author":"CR Jack Jr","year":"2008","unstructured":"Jack CR Jr., Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D, Borowski B, Britson PJ, Ward JLW. The Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging. 2008;27:685\u201391.","journal-title":"J Magn Reson Imaging"},{"key":"7939_CR35","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.neuroimage.2006.01.021","volume":"31","author":"RS Desikan","year":"2006","unstructured":"Desikan RS, S\u00e9gonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, Buckner RL, Dale AM, Maguire RP, Hyman BT, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. NeuroImage. 2006;31:968\u201380.","journal-title":"NeuroImage"},{"key":"7939_CR36","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease. Neurology. 1984;34:939\u201344.","journal-title":"Neurology"},{"key":"7939_CR37","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1365-2796.2004.01388.x","volume":"256","author":"RC Petersen","year":"2004","unstructured":"Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183\u201394.","journal-title":"J Intern Med"},{"key":"7939_CR38","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1212\/WNL.0b013e318204a397","volume":"76","author":"S Kim","year":"2011","unstructured":"Kim S, Swaminathan S, Shen L, Risacher SL, Nho K, Foroud T, Shaw LM, Trojanowski JQ, Potkin SG, Huentelman MJ, et al. Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort. Neurology. 2011;76:69\u201379.","journal-title":"Neurology"},{"key":"7939_CR39","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/01.pra.0000393841.25723.70","volume":"17","author":"TJ Ingenhoven","year":"2011","unstructured":"Ingenhoven TJ, van den Brink W, Passchier J, Duivenvoorden HJ. Treatment-disrupting behaviors during psychotherapy of patients with personality disorders: the predictive power of psychodynamic personality diagnosis. J Psychiatr Pract. 2011;17:21\u201334.","journal-title":"J Psychiatr Pract"},{"key":"7939_CR40","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/ene.15160","volume":"29","author":"L Li","year":"2022","unstructured":"Li L, Xu W, Tan CC, Cao XP, Wei BZ, Dong CW, Tan L. A gene-environment interplay between omega-3 supplementation and APOE \u03b54 provides insights for Alzheimer\u2019s disease precise prevention amongst high-genetic-risk population. Eur J Neurol. 2022;29:422\u201331.","journal-title":"Eur J Neurol"},{"key":"7939_CR41","doi-asserted-by":"publisher","first-page":"e213676","DOI":"10.1212\/WNL.0000000000213676","volume":"104","author":"F Gonzalez-Ortiz","year":"2025","unstructured":"Gonzalez-Ortiz F, Kirsebom BE, Yakoub Y, Gundersen JK, P\u00e5lhaugen L, Waterloo K, Selnes P, Jarholm JA, G\u00edslad\u00f3ttir B, Rongve A, et al. Associations Between Changes in Levels of Phosphorylated Tau and Severity of Cognitive Impairment in Early Alzheimer Disease. Neurology. 2025;104:e213676.","journal-title":"Neurology"},{"key":"7939_CR42","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","volume":"81","author":"NJ Ashton","year":"2024","unstructured":"Ashton NJ, Brum WS, Di Molfetta G, Benedet AL, Arslan B, Jonaitis E, Langhough RE, Cody K, Wilson R, Carlsson CM, et al. Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology. JAMA Neurol. 2024;81:255\u201363.","journal-title":"JAMA Neurol"},{"key":"7939_CR43","doi-asserted-by":"publisher","first-page":"e2545862","DOI":"10.1001\/jamanetworkopen.2025.45862","volume":"8","author":"C Trieu","year":"2025","unstructured":"Trieu C, van Harten AC, van Leeuwenstijn M, Schl\u00fcter LM, Boonkamp L, Aladdin A, Sikkes SAM, van de Giessen E, Verberk IMW, Teunissen CE, van der Flier WM. Longitudinal Blood-Based Biomarkers and Clinical Progression in Subjective Cognitive Decline. JAMA Netw Open. 2025;8:e2545862.","journal-title":"JAMA Netw Open"},{"key":"7939_CR44","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/s43587-025-00835-z","volume":"5","author":"R Ossenkoppele","year":"2025","unstructured":"Ossenkoppele R, Salvad\u00f3 G, Janelidze S, Pichet Binette A, Bali D, Karlsson L, Palmqvist S, Mattsson-Carlgren N, Stomrud E, Therriault J, et al. Plasma p-tau217 and tau-PET predict future cognitive decline among cognitively unimpaired individuals: implications for clinical trials. Nat Aging. 2025;5:883\u201396.","journal-title":"Nat Aging"},{"key":"7939_CR45","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1001\/jamaneurol.2024.2619","volume":"81","author":"S Janelidze","year":"2024","unstructured":"Janelidze S, Barth\u00e9lemy NR, Salvad\u00f3 G, Schindler SE, Palmqvist S, Mattsson-Carlgren N, Braunstein JB, Ovod V, Bollinger JG, He Y, et al. Plasma Phosphorylated Tau 217 and A\u03b242\/40 to Predict Early Brain A\u03b2 Accumulation in People Without Cognitive Impairment. JAMA Neurol. 2024;81:947\u201357.","journal-title":"JAMA Neurol"},{"key":"7939_CR46","doi-asserted-by":"crossref","unstructured":"Chen X, Jiang M, Zhang L, Zhu J, Li A, He Z, Zhou X, Zhu Y, Zhang C, Wang C, et al. Association of plasma p-tau and p-tau\/A\u03b2 ratio with Alzheimer\u2019s pathology. J Prev Alzheimers Dis. 2026:100472.","DOI":"10.1016\/j.tjpad.2025.100472"},{"key":"7939_CR47","doi-asserted-by":"publisher","first-page":"6506","DOI":"10.1002\/alz.14140","volume":"20","author":"DJ Figdore","year":"2024","unstructured":"Figdore DJ, Griswold M, Bornhorst JA, Graff-Radford J, Ramanan VK, Vemuri P, Lowe VJ, Knopman DS, Jack CR Jr., Petersen RC, Algeciras-Schimnich A. Optimizing cutpoints for clinical interpretation of brain amyloid status using plasma p-tau217 immunoassays. Alzheimers Dement. 2024;20:6506\u201316.","journal-title":"Alzheimers Dement"},{"key":"7939_CR48","doi-asserted-by":"crossref","unstructured":"Brum WS. Cost\u2011effective Alzheimer\u2019s disease detection using plasma p\u2011tau217\u2011based risk stratification. Nat Aging. 2023;3(9):1053\u20131054.","DOI":"10.1038\/s43587-023-00485-z"},{"key":"7939_CR49","doi-asserted-by":"publisher","first-page":"105805","DOI":"10.1016\/j.ebiom.2025.105805","volume":"117","author":"S Lehmann","year":"2025","unstructured":"Lehmann S, Gabelle A, Duchiron M, Busto G, Morchikh M, Delaby C, Hirtz C, Mondesert E, Cristol JP, Barnier-Figue G, et al. Comparative performance of plasma pTau181\/A\u03b242, pTau217\/A\u03b242 ratios, and individual measurements in detecting brain amyloidosis. EBioMedicine. 2025;117:105805.","journal-title":"EBioMedicine"},{"key":"7939_CR50","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S1474-4422(21)00214-3","volume":"20","author":"EH Thijssen","year":"2021","unstructured":"Thijssen EH, La Joie R, Strom A, Fonseca C, Iaccarino L, Wolf A, Spina S, Allen IE, Cobigo Y, Heuer H, et al. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer\u2019s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol. 2021;20:739\u201352.","journal-title":"Lancet Neurol"},{"key":"7939_CR51","doi-asserted-by":"publisher","first-page":"907","DOI":"10.3233\/JAD-231114","volume":"98","author":"J Cao","year":"2024","unstructured":"Cao J, Tang Y, Chen S, Yu S, Wan K, Yin W, Zhen W, Zhao W, Zhou X, Zhu X, Sun Z. The Hippocampal Subfield Volume Reduction and Plasma Biomarker Changes in Mild Cognitive Impairment and Alzheimer\u2019s Disease. J Alzheimers Dis. 2024;98:907\u201323.","journal-title":"J Alzheimers Dis"},{"key":"7939_CR52","doi-asserted-by":"publisher","first-page":"7120","DOI":"10.1007\/s00415-024-12674-w","volume":"271","author":"M Mitolo","year":"2024","unstructured":"Mitolo M, Lombardi G, Manca R, Nacmias B, Venneri A. Association between blood-based protein biomarkers and brain MRI in the Alzheimer\u2019s disease continuum: a systematic review. J Neurol. 2024;271:7120\u201340.","journal-title":"J Neurol"},{"key":"7939_CR53","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1001\/jamaneurol.2021.2293","volume":"78","author":"MM Mielke","year":"2021","unstructured":"Mielke MM, Frank RD, Dage JL, Jeromin A, Ashton NJ, Blennow K, Karikari TK, Vanmechelen E, Zetterberg H, Algeciras-Schimnich A, et al. Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes. JAMA Neurol. 2021;78:1108\u201317.","journal-title":"JAMA Neurol"},{"key":"7939_CR54","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1001\/jamaneurol.2021.4654","volume":"79","author":"A Leuzy","year":"2022","unstructured":"Leuzy A, Smith R, Cullen NC, Strandberg O, Vogel JW, Binette AP, Borroni E, Janelidze S, Ohlsson T, J\u00f6gi J, et al. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease. JAMA Neurol. 2022;79:149\u201358.","journal-title":"JAMA Neurol"},{"key":"7939_CR55","doi-asserted-by":"publisher","first-page":"111739","DOI":"10.1016\/j.fct.2020.111739","volume":"145","author":"S Ahmed","year":"2020","unstructured":"Ahmed S, Hasan MM, Heydari M, Rauf A, Bawazeer S, Abu-Izneid T, Rebezov M, Shariati MA, Daglia M, Rengasamy KR. Therapeutic potentials of crocin in medication of neurological disorders. Food Chem Toxicol. 2020;145:111739.","journal-title":"Food Chem Toxicol"},{"key":"7939_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10753-022-01721-1","volume":"46","author":"S Thakur","year":"2023","unstructured":"Thakur S, Dhapola R, Sarma P, Medhi B, Reddy DH. Neuroinflammation in Alzheimer\u2019s Disease: Current Progress in Molecular Signaling and Therapeutics. Inflammation. 2023;46:1\u201317.","journal-title":"Inflammation"},{"key":"7939_CR57","doi-asserted-by":"publisher","first-page":"113797","DOI":"10.1016\/j.biopha.2022.113797","volume":"155","author":"S Ahmed","year":"2022","unstructured":"Ahmed S, Alam W, Aschner M, Alsharif KF, Albrakati A, Saso L, Khan H. Natural products targeting the ATR-CHK1 signaling pathway in cancer therapy. Biomed Pharmacother. 2022;155:113797.","journal-title":"Biomed Pharmacother"},{"key":"7939_CR58","doi-asserted-by":"publisher","first-page":"111658","DOI":"10.1016\/j.ejmech.2019.111658","volume":"183","author":"S Ahmed","year":"2019","unstructured":"Ahmed S, Khan H, Mirzaei H. Mechanics insights of curcumin in myocardial ischemia: Where are we standing? Eur J Med Chem. 2019;183:111658.","journal-title":"Eur J Med Chem"},{"key":"7939_CR59","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1002\/alz.12892","volume":"19","author":"B Rajbanshi","year":"2023","unstructured":"Rajbanshi B, Guruacharya A, Mandell JW, Bloom GS. Localization, induction, and cellular effects of tau phosphorylated at threonine 217. Alzheimers Dement. 2023;19:2874\u201387.","journal-title":"Alzheimers Dement"},{"key":"7939_CR60","doi-asserted-by":"publisher","first-page":"115289","DOI":"10.1016\/j.bbr.2024.115289","volume":"477","author":"F Motolese","year":"2025","unstructured":"Motolese F, Norata D, Iaccarino G, Sapio E, Capone F. The effect of creatinine level on amyloid-\u03b2 and tau plasma concentrations in a cohort of Alzheimer\u2019s disease patients without kidney disease. Behav Brain Res. 2025;477:115289.","journal-title":"Behav Brain Res"},{"key":"7939_CR61","doi-asserted-by":"publisher","first-page":"e210287","DOI":"10.1212\/WNL.0000000000210287","volume":"104","author":"JA Bornhorst","year":"2025","unstructured":"Bornhorst JA, Lundgreen CS, Weigand SD, Figdore DJ, Wiste H, Griswold M, Vemuri P, Graff-Radford J, Knopman DS, Cogswell P, et al. Quantitative Assessment of the Effect of Chronic Kidney Disease on Plasma p-tau217 Concentrations. Neurology. 2025;104:e210287.","journal-title":"Neurology"},{"key":"7939_CR62","doi-asserted-by":"publisher","first-page":"e258842","DOI":"10.1001\/jamanetworkopen.2025.8842","volume":"8","author":"SH Kang","year":"2025","unstructured":"Kang SH, Lee EH, Kim YJ, Jang H, Shin D, Zetterberg H, Blennow K, Gonzalez-Ortiz F, Ashton NJ, Yun J, et al. Cerebral Amyloid Angiopathy and Downstream Alzheimer Disease Plasma Biomarkers. JAMA Netw Open. 2025;8:e258842.","journal-title":"JAMA Netw Open"},{"key":"7939_CR63","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/s41591-022-01822-2","volume":"28","author":"MM Mielke","year":"2022","unstructured":"Mielke MM, Dage JL, Frank RD, Algeciras-Schimnich A, Knopman DS, Lowe VJ, Bu G, Vemuri P, Graff-Radford J, Jack CR Jr., Petersen RC. Performance of plasma phosphorylated tau 181 and 217 in the community. Nat Med. 2022;28:1398\u2013405.","journal-title":"Nat Med"},{"key":"7939_CR64","doi-asserted-by":"publisher","first-page":"e70426","DOI":"10.1002\/alz.70426","volume":"21","author":"MD Rudolph","year":"2025","unstructured":"Rudolph MD, Sutphen CL, Register TC, Lockhart SN, Rundle MM, Hughes TM, Bateman JR, Sai KKS, Whitlow CT, Craft S, Mielke MM. Evaluation of plasma p-tau217 for detecting amyloid pathology in a heterogeneous community-based cohort. Alzheimers Dement. 2025;21:e70426.","journal-title":"Alzheimers Dement"},{"key":"7939_CR65","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1136\/jnnp-2025-335830","volume":"96","author":"J Ahn","year":"2025","unstructured":"Ahn J, Lee EH, Yoo H, Shin D, Kang H, Yim S, Kim S, Kim K, Yoon S, Zetterberg H, et al. Tailoring thresholds for interpreting plasma p-tau217 levels. J Neurol Neurosurg Psychiatry. 2025;96:722\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"7939_CR66","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s13195-024-01521-9","volume":"16","author":"MD Howe","year":"2024","unstructured":"Howe MD, Britton KJ, Joyce HE, Menard W, Emrani S, Kunicki ZJ, Faust MA, Dawson BC, Riddle MC, Huey ED, et al. Clinical application of plasma p-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer\u2019s disease. Alzheimers Res Ther. 2024;16:154.","journal-title":"Alzheimers Res Ther"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-07939-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07939-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07939-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T16:03:38Z","timestamp":1772467418000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-07939-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7939"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-07939-z","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"12 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by institutional review boards of all participating institutions, and written informed consent was obtained from all participants or their guardians according to the Declaration of Helsinki (consent for research). The ADNI was approved by the Institutional Review Boards (IRB) all participating centers.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"305"}}